Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New peptides to fight ovarian cancer drug resistance

02.08.2011
Italian and German scientists have designed peptides to target the protein-protein interface of a key enzyme in DNA synthesis crucial for cancer growth.

The peptides act by a novel inhibitory mechanism and curb cancer cell growth in drug resistant ovarian cancer cells. The interdisciplinary research project was led by the University of Modena and Reggio Emilia (UNIMORE) and the Heidelberg Institute for Theoretical Studies (HITS).


Structure of human thymidylate synthase with an inhibitory peptide bound at its dimer interface determined by x-ray crystallography. The protein is shown with a cartoon representation of its secondary structure colored according to sequence and the peptide is colored by atom-type with its electron density contoured in blue. Picture: Cardinale et al., PNAS (2011) 27 July 2011

Worldwide, over 200,000 women are diagnosed with ovarian cancer every year, with higher incidence in developed countries where it is the fifth leading cause of cancer-related deaths in women. Ovarian cancer has a high mortality rate due to frequent late diagnosis and the rapid development of drug resistance. Several clinically important anti-cancer drugs that are widely used in chemotherapy inhibit the enzyme, thymidylate synthase, which plays a key role in DNA synthesis. However, the use of these drugs is associated with drug resistance and new compounds with different inhibitory mechanisms are required to combat resistance.

Scientists from Italy and Germany have designed octapeptides that specifically target the protein-protein interface of thymidylate synthase. Thymidylate synthase is composed of two identical polypeptide chains, i.e. it is a homodimer. The peptides stabilize the inactive form of the enzyme, show a novel mechanism of inhibition for homodimeric enzymes, and inhibit cell growth in drug sensitive and resistant cancer cell lines.

The interdisciplinary collaboration between scientists in Italy and Germany, led by Maria Paola Costi and Glauco Ponterini at the University of Modena and Reggio Emilia, Stefano Mangani at the University of Siena (UNISI) and Rebecca Wade at Heidelberg Institute for Theoretical Studies (HITS), was part of the LIGHTS project (LIGands to interfere with human TS). The project was supported by the Sixth Framework Programme (FP6), an EU scheme to fund and promote European research and technological development.

The researchers have discovered several peptides that inhibit thymidylate synthase by modulating protein-protein interactions. Maria Paola Costi explains: “These peptides have sequences from the protein-protein interface of the enzyme and inhibit it by binding to a previously unknown allosteric binding site - that is, a site other than the protein's active site - at the protein-protein interface.” By a combination of experimental and computational approaches, it was shown that their inhibitory mechanism involving stabilization of an inactive form of the catalytic protein differs from those of protein-protein interface inhibitors reported to date.

Unlike the existing drugs targeting thymidylate synthase, these peptides inhibit intra-cellular thymidylate synthase and cell growth without leading to increased levels of thymidylate synthase protein when administered to ovarian cancer cells. “This observation indicates the potential value of these peptides in overcoming drug resistance problems, although the cellular effects remain to be fully explored,” says Rebecca Wade. Further steps will require optimization of the compounds discovered and detailed analysis of their cellular mechanism of action. The concepts revealed by this work can be expected to provide new avenues for the development of drugs for combating diseases such as ovarian cancer.

The original scientific article:
Cardinale et al., Protein-protein interface-binding peptides inhibit the cancer therapy target human thymidylate synthase. PNAS (2011) 27 July 2011 (published online before print).

doi: 10.1073/pnas.1104829108

http://www.pnas.org/cgi/doi/10.1073/pnas.1104829108

Press Contact
Dr. Peter Saueressig
Public Relations
Heidelberg Institute for Theoretical Studies (HITS)
Phone: +49-6221-533-245
Fax: +49-6221-533-198
peter.saueressig@h-its.org
www.h-its.org
Scientific Contacts
Prof. Maria Paola Costi
Dipartimento di Scienze Farmaceutiche,
Universita degli Studi di Modena e Reggio Emilia,
Via Campi 183,
41100 Modena,
Italy
Phone 0039-0592055125
Fax 0039-0592055131
mariapaola.costi@unimore.it
Prof. Stefano Mangani
Dipartimento di Chimica,
Università degli Studi di Siena,
Via Aldo Moro 2,
53100 Siena,
Italy
Phone 0039-0577-234255
Fax 0039-0577-243233
mangani@unisi.it
Dr. Rebecca Wade
Molecular and Cellular Modeling Group
Heidelberg Institute for Theoretical Studies (HITS)
Schloss-Wolfsbrunnenweg 35
69118 Heidelberg
Germany
Phone: +49 (0)6221 - 533 - 247
Fax: +49 (0)6221 - 533 - 298
rebecca.wade@h-its.org
University of Modena and Reggio Emilia (UNIMORE) is one of the oldest universities in Europe and currently has more than 20,000 students. Eight of the twelve faculties are located in Modena, among them the Biotechnology and Bioscience faculty with the Department of Pharmaceutical Sciences.

www.unimore.it

University of Siena (UNISI) is one of the oldest universities in Italy and currently has around 20,000 students. The university has nine schools, one of them being the School of Mathematical, Physical and Natural Sciences with the Department of Chemistry.

http://www.unisi.it

HITS (Heidelberg Institute for Theoretical Studies) is a private, non-profit research institute carrying out multidisciplinary research in the computational sciences. It was established in 2010 as a successor to the EML Research. HITS receives its base funding from the Klaus Tschira Foundation, which was established in 1995.

www.h-its.org

Dr. Peter Saueressig | idw
Further information:
http://www.h-its.org

More articles from Life Sciences:

nachricht Rutgers scientists discover 'Legos of life'
23.01.2018 | Rutgers University

nachricht Researchers identify a protein that keeps metastatic breast cancer cells dormant
23.01.2018 | Institute for Research in Biomedicine (IRB Barcelona)

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Optical Nanoscope Allows Imaging of Quantum Dots

Physicists have developed a technique based on optical microscopy that can be used to create images of atoms on the nanoscale. In particular, the new method allows the imaging of quantum dots in a semiconductor chip. Together with colleagues from the University of Bochum, scientists from the University of Basel’s Department of Physics and the Swiss Nanoscience Institute reported the findings in the journal Nature Photonics.

Microscopes allow us to see structures that are otherwise invisible to the human eye. However, conventional optical microscopes cannot be used to image...

Im Focus: Artificial agent designs quantum experiments

On the way to an intelligent laboratory, physicists from Innsbruck and Vienna present an artificial agent that autonomously designs quantum experiments. In initial experiments, the system has independently (re)discovered experimental techniques that are nowadays standard in modern quantum optical laboratories. This shows how machines could play a more creative role in research in the future.

We carry smartphones in our pockets, the streets are dotted with semi-autonomous cars, but in the research laboratory experiments are still being designed by...

Im Focus: Scientists decipher key principle behind reaction of metalloenzymes

So-called pre-distorted states accelerate photochemical reactions too

What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...

Im Focus: The first precise measurement of a single molecule's effective charge

For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.

Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...

Im Focus: Paradigm shift in Paris: Encouraging an holistic view of laser machining

At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.

No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

10th International Symposium: “Advanced Battery Power – Kraftwerk Batterie” Münster, 10-11 April 2018

08.01.2018 | Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

 
Latest News

Rutgers scientists discover 'Legos of life'

23.01.2018 | Life Sciences

Seabed mining could destroy ecosystems

23.01.2018 | Earth Sciences

Transportable laser

23.01.2018 | Physics and Astronomy

VideoLinks Science & Research
Overview of more VideoLinks >>>